Facebook Pixel When can India become a global gateway for the medtech industry? | Bio Spectrum - business - Les denne historien på Magzter.com

Prøve GULL - Gratis

When can India become a global gateway for the medtech industry?

Bio Spectrum

|

BioSpectrum Indian Feb 2025

Over 70 per cent of innovations by Indian medical technology startups are powered by digital integration, driven by a convergence of factors accelerating the industry's growth, according to a recent report by EY. Additionally, government initiatives are playing a pivotal role in positioning India as a global medtech hub. And the growing US FDA approvals is providing the required recognition to Indian medical technologies. Would these developments eventually lead to import independence for the Indian medtech sector?

- Vrushti Kothari

When can India become a global gateway for the medtech industry?

The Indian medtech market, valued at $12 billion in 2023-24, is projected to reach $50 billion by 2030, with India's global market share set to grow from 1.65 per cent to 10-12 per cent over the next 25 years. Further, Indian medtech exports reached $3.8 billion in 2023-24, with the US as the primary market. Although India is still import dependent in the medtech sector, the growing number of startups in this space are moving the tailwinds in a global direction.

Over the past few years, medtech startups have emerged as trailblazers, using innovation to bridge gaps, solve pressing challenges, and unlocking new possibilities in healthcare. This growth is particularly crucial in India, where healthcare challenges include vast geographical disparities, increasing disease burdens, and affordability constraints.

For example, artificial intelligence (AI)-driven diagnostic solutions are helping healthcare providers detect diseases at earlier stages, while wearable devices are empowering individuals to monitor their health in real time. As a result, Indian medtech startups are actively integrating digital solutions such as AI, IoT, and cloud computing to democratise healthcare with portable devices, remote monitoring and screening tools. Taking a few examples, BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, is revolutionising the diagnosis and treatment of complex brain disorders through its technology platform, VoxelBox. Likewise, another Bengalurubased startup 4baseCare is using advanced genomics and digital health technology to offer cutting-edge precision oncology solutions.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

MAHE teams up with OpenAI to integrate AI to enhance outcomes

Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Jubilant Bhartia Foundation & McGill University to launch CoE in AI education

The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Heeding Auditory Warning Signs

By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).

time to read

2 mins

April 2026

Bio Spectrum

Bio Spectrum

Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer

Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer

Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow

Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

UK deploys new bone scanners to help prevent fractures

Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Cytiva expands Fast Trak process development and validation services facility in India

Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

ΑΙ TAKES INDIAN PHARMA REINS

The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.

time to read

10 mins

April 2026

Bio Spectrum

NIH halts arm of clinical trial evaluating potential stroke treatment

The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).

time to read

1 min

April 2026

Listen

Translate

Share

-
+

Change font size